Oncolytics Biotech Reports Submission Of A Type C Meeting Request To FDA
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech has submitted a Type C meeting request to the FDA to discuss its planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer. The company anticipates meeting with the FDA in Q2 2024, aiming for a transformative year with the expected overall survival data from the BRACELET-1 study.

April 11, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncolytics Biotech's submission of a Type C meeting request to the FDA for pelareorep in metastatic breast cancer marks a significant regulatory step, potentially impacting its stock positively.
The submission of a Type C meeting request to the FDA by Oncolytics Biotech is a critical regulatory step, indicating progress in the development of pelareorep for metastatic breast cancer. This development is likely to be viewed positively by investors, as it demonstrates the company's commitment to advancing its pipeline and potentially bringing a new treatment to market. The anticipation of a transformative year with expected overall survival data from the BRACELET-1 study further underscores the potential positive impact on the company's valuation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100